Literature DB >> 31021469

Influence of abutment height and implant depth position on interproximal peri-implant bone in sites with thin mucosa: A 1-year randomized clinical trial.

Alexandre Pico1, Pablo Martín-Lancharro2, Leticia Caneiro1, Lourdes Nóvoa1, Pilar Batalla1, Juan Blanco1,3.   

Abstract

OBJECTIVES: The aim of this RCT was to assess radiographically the effect of abutment height and depth of placement of platform-switched implants on interproximal peri-implant bone loss (IPBL) in patients with thin peri-implant mucosa.
MATERIAL AND METHODS: Thirty-three patients received one prosthesis supported by two implants replacing at least two adjacent missing teeth (66 implants). Patients were randomly allocated and implant insertion depth adapted to abutment height groups (3 mm height group the implants were placed 2 mm subcrestally; 1 mm height group, equicrestally). Clinical and radiological measurements were performed at 3, 6 and 12 months after surgery. Interproximal bone-level changes were compared between treatment groups using repeated measures mixed ANOVA. The association between IPBL and categorical variables was also analyzed.
RESULTS: The mean IPBL in 1 mm abutment group was 0.76 ± 0.79 mm at 3 months, 0.92 ± 0.88 mm at 6 months, and 0.95 ± 0.88 mm at 12 months, while in the 3 mm abutment group was 0.06 ± 0.21, 0.07 ± 0.22 mm, and 0.12 ± 0.33 mm, respectively. Significant differences between both groups were observed at every time point. When the influence of patient characteristics and clinical variables was analyzed, no statistically significant differences were also observed.
CONCLUSIONS: The use of long abutments, in combination with subcrestal implant position in sites with thin mucosa, led to lower IPBL in comparison with the use of short abutments.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  abutment height; implant-abutment connection; interproximal bone loss; platform switching; thin mucosa

Mesh:

Year:  2019        PMID: 31021469     DOI: 10.1111/clr.13443

Source DB:  PubMed          Journal:  Clin Oral Implants Res        ISSN: 0905-7161            Impact factor:   5.977


  2 in total

1.  Carfilzomib inhibits the proliferation and apoptosis of multiple myeloma cells by inhibiting STAT1/COX-2/iNOS signaling pathway.

Authors:  Shaolong He; Weiwei Tian; Jie Zhao; Rong Gong; Tao Wang; Liangming Ma
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

2.  Analysis of Peri-Implant Bone Loss with a Convergent Transmucosal Morphology: Retrospective Clinical Study.

Authors:  María Costa Castillo; Martín Laguna Martos; Rocío Marco Pitarch; Marina García Selva; Silvia Del Cid Rodríguez; Carla Fons-Badal; Rubén Agustín Panadero
Journal:  Int J Environ Res Public Health       Date:  2022-03-15       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.